Live Feeds
● TRACKER Updated 16d ago Β· 52 sources tracked

Blood pressure medication recalled nationwide. See affected drug

Over 3,000 bottles of blood pressure medication have been recalled nationwide due to failure in quality testing. The FDA cited failure to meet dissolution standards, referring to how a tablet dissolves during testing. Patients currently taking the impacted medications must verify their prescriptions and consult a pharmacist to ensure safety.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (52)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ The FDA issued a nationwide recall for blood pressure medication due to excessive levels of telmisartan.
  • βœ“ The affected pills carry risks associated with superpotent elements.
  • βœ“ Patients currently taking the impacted medications must verify their prescriptions and consult a pharmacist to ensure safety.
  • βœ“ The FDA cited failure to meet dissolution standards.
πŸ›‘οΈ Source Corroboration: 52 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The number of recalled bottles was updated to over 3,000 from nearly 22,000 previously reported.

Live updates

  1. Blood pressure medication recalled nationwide

    Over 3,000 bottles of blood pressure medication have been recalled nationwide due to failure in quality testing. The FDA cited failure to meet dissolution standards, referring to how a tablet dissolves during testing. Patients currently taking the impacted medications must verify their prescriptions and consult a pharmacist to ensure safety.

    Why it matters

    The recall was issued due to risks associated with superpotent elements and failure in quality testing. Regulatory agencies continue to monitor the situation closely. This recall affects a specific blood pressure medication, and patients are advised to consult their pharmacists.

    What is confirmed

    • The FDA issued a nationwide recall for blood pressure medication due to excessive levels of telmisartan.
    • The affected pills carry risks associated with superpotent elements.
    • Patients currently taking the impacted medications must verify their prescriptions and consult a pharmacist to ensure safety.
    • The FDA cited failure to meet dissolution standards.

    What to watch next

    • Further updates on the recall and potential health risks.
    • Actions taken by regulatory agencies to address the issue.
    • Additional information on the affected medication and its distribution.
    Sources used for this update (6)
    1. www.foxbusiness.com β€” Great Business Leaders in America & Around the World | Fox Business
    2. www.newsbreak.com β€” Cathie Wood Predicts Oil Crashing to $30-$35 a Barrel as EVs Take Over Transportation: Says Demand Is 'Peaking’
    3. www.medicaldaily.com β€” Salmonella Found in All Eight Oyster Samples From Virginia's Closed Little Wicomico River as Case Counts Diverge
    4. www.thehealthy.com β€” FDA: More Than 3,000 Bottles of Blood Pressure Drug Recalled ...
    5. www.ntd.com β€” Blood Pressure Drug Recalled Nationwide for Failing Quality ...
    6. www.ntd.com β€” Blood Pressure Drug Recalled Nationwide for Failing Quality Testing
    confidence 90%
  2. Nationwide Blood Pressure Medication Recall Issued

    Federal health officials issued a nationwide recall for nearly 22,000 bottles of blood pressure medication due to excessive levels of telmisartan. The Food and Drug Administration warned that the affected pills carry risks associated with superpotent elements. Patients currently taking the impacted medications must verify their prescriptions and consult a pharmacist to ensure safety. Regulatory agencies continue to monitor the situation closely as separate pharmaceutical actions involve other federal drug safety notices.

    Why it matters

    The Food and Drug Administration issued the recall earlier in October after finding that some batches contain too much telmisartan. Federal health officials warn that these elevated drug levels pose potential health risks to consumers. Patients are advised to check their medicine cabinets immediately and speak with healthcare professionals regarding safety precautions.

    What is confirmed

    • Federal health officials report a nationwide recall of nearly 22,000 bottles of blood pressure medication due to excessive amounts of telmisartan.
    • The Food and Drug Administration issued the recall earlier in October after warning that affected drug batches contain too much telmisartan.
    • Blood pressure medication sold nationwide was recalled due to potential excess drug levels.

    Still unconfirmed

    • Over 20,000 bottles of blood pressure medication were recalled nationwide according to Yahoo reporting by Lily Menk.

    What to watch next

    • Additional updates from the Food and Drug Administration regarding specific affected product lots.
    • Pharmacist guidance on returning or exchanging impacted blood pressure medication bottles.
    Sources used for this update (4)
    1. www.yahoo.com β€” Over 20,000 Bottles of Blood Pressure Medication Recalled ...
    2. www.yahoo.com β€” Blood pressure medication recalled due to potential ... - Yahoo
    3. www.express.co.uk β€” Urgent blood pressure drug recall issued over 'super potent ...
    4. sideeffectsbase.com β€” FDA Drug Recall List 2026: How to Check Your Medication
    confidence 90%
  3. Nationwide Blood Pressure Medication Recall Expands

    Federal health officials report a nationwide recall of nearly 22,000 bottles of blood pressure medication due to the presence of excessive amounts of telmisartan. Food and Drug Administration officials warn that the affected drugs run a risk of containing a superpotent element. Patients taking the impacted medications must verify their prescriptions and consult with a pharmacist to ensure safety. Regulatory agencies continue to monitor the situation closely while separate pharmaceutical actions involve other federal drug safety notices.

    Why it matters

    The Food and Drug Administration oversees product safety across the United States pharmaceutical supply chain, stepping in when manufacturing deviations threaten patient health. Superpotent ingredients in prescription drugs can lead to severe adverse medical events, prompting mandatory or voluntary recalls by manufacturers. Regulatory oversight helps mitigate risks for patients relying on daily cardiovascular treatments.

    What is confirmed

    • Nearly 22,000 bottles of blood pressure medication were recalled nationwide.
    • The recall involves tablets that may contain excessive amounts of telmisartan and carry a risk of a superpotent element.

    Still unconfirmed

    • GLP-1 medications are undergoing a separate nationwide recall that was updated by the FDA to a higher risk level after being initiated in September.

    What to watch next

    • Further updates from the Food and Drug Administration regarding affected lot numbers
    • Guidance on return or disposal procedures for patients possessing recalled bottles
    Sources used for this update (5)
    1. help.naver.com β€” Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    2. www.yahoo.com β€” FDA Announces Nationwide Recall of GLP-1 Medications ... - Yahoo
    3. www.ntd.com β€” Blood Pressure Medication Recalled Nationwide Over β€˜Superpotent Drug’ | NTD
    4. itsrecalled.com β€” Drug & medication recalls this week β€” latest U.S. recalls ...
    5. www.medicaldaily.com β€” Cardinal Health Procedure Kits May Contain Recalled BD Alaris ...
    confidence 100%
  4. Blood Pressure Medication Recall Expands

    Federal health officials warn that a nationwide recall of blood pressure and heart medication involves nearly 22,000 bottles due to products being too strong. Food and Drug Administration officials state that the affected medication runs a risk of containing a superpotent element. Patients taking the impacted drugs should verify their prescriptions and consult with a pharmacist to ensure safety while regulatory agencies monitor the situation.

    Why it matters

    Drug recalls require careful coordination between regulatory agencies and manufacturers to prevent adverse patient reactions. Previous actions by Inventia Healthcare Limited involved thousands of bottles of Chlorthalidone Tablets failing dissolution tests, while separate issues affected Argatroban Injection and metoprolol succinate. Monitoring these supply chain failures helps clinicians and patients avoid substandard medications.

    What is confirmed

    • Nearly 22,000 bottles of blood pressure and heart medication have been recalled because the medications were too strong.
    • FDA officials say there is a chance that the medication could contain a superpotent element.

    What to watch next

    • Additional updates from the FDA regarding affected lot numbers and manufacturer details
    • Guidance from pharmacists on returning or exchanging recalled medication bottles
    Sources used for this update (6)
    1. www.everydayhealth.com β€” Health News: Latest Research, Top Stories, Trending Topics
    2. www.yahoo.com β€” Yahoo
    3. www.psychiatrictimes.com β€” ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality | Psychiatric Times
    4. sg.news.yahoo.com β€” Blood Pressure Drug Recall: More Than 21,000 Bottles Involved ...
    5. article.wn.com β€” Nearly 22,000 Bottles of Blood Pressure Medication Recalled ...
    6. recalls.watch β€” Recall Check: Product, Food, Drug and Vehicle Recalls
    confidence 80%
  5. Nationwide Recalls Impact Blood Pressure and Hospital Medications

    Inventia Healthcare Limited expanded a nationwide recall of Chlorthalidone Tablets USP, 25 milligrams, encompassing more than 25,000 bottles after failing multiple dissolution tests. The Food and Drug Administration classified this September action as a Class II risk level, indicating that potential medical effects are temporary or reversible and the chance of serious harm is remote. Patients using the medication should check their prescriptions with a pharmacist. Additionally, Par Health recalled 22 lots of Argatroban Injection due to particulate matter, and Dr Reddy Laboratories previously recalled 13,560 bottles of metoprolol succinate.

    Why it matters

    Pharmaceutical recalls disrupt medication supplies and require patients and hospitals to verify affected batch numbers to ensure safety. Regulatory classifications help healthcare providers assess the severity of manufacturing defects. These actions highlight ongoing quality control challenges across the drug manufacturing sector.

    What is confirmed

    • Inventia Healthcare Limited expanded a voluntary nationwide recall of Chlorthalidone Tablets USP, 25 milligrams, to more than 25,000 bottles due to failed dissolution tests.
    • The Food and Drug Administration classified the Chlorthalidone recall as a Class II risk level.
    • Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL to the hospital or user level due to particulate matter identified as cellulose, polystyrene, and polyethylene terepht.
    • Dr Reddy Laboratories previously recalled 13,560 bottles of metoprolol succinate in the United States.

    What to watch next

    • Further updates from the Food and Drug Administration regarding the scope of the Inventia Healthcare and Par Health recalls.
    • Reports from pharmacies confirming how many affected Chlorthalidone and Argatroban units remain with consumers or hospitals.
    Sources used for this update (4)
    1. www.fda.gov β€” Drug Alerts and Statements | FDA
    2. www.foxbusiness.com β€” Health Care
    3. toledolaw.com β€” Dr Reddy’s Recalls Generic Hypertension Drug | Zoll & Kranz
    4. www.fda.gov β€” Par Health Issues Voluntary Nationwide Recall of Argatroban ...
    confidence 100%
  6. Inventia Recalls Blood Pressure Pills Nationwide

    Inventia Healthcare Limited expanded a voluntary nationwide recall of blood pressure medication to more than 25,000 bottles after multiple dissolution tests failed. The affected medication includes Chlorthalidone Tablets, United States Pharmacopeia, 25 milligrams. Patients taking the drug should contact their pharmacist to check if their prescriptions belong to the recalled batches. The Food and Drug Administration classified the September recall action as a Class II risk level. This classification means the chance of serious harm is remote and potential medical effects are temporary or reversible.

    Why it matters

    Drug recalls require immediate attention from consumers to prevent health risks from substandard pharmaceuticals. Regulatory oversight by the Food and Drug Administration ensures that medications failing quality standards are removed from the supply chain. Dissolution test failures indicate that a tablet may not break down properly in the body, potentially impacting how the active ingredient is absorbed.

    What is confirmed

    • Inventia Healthcare Limited expanded a voluntary nationwide recall of blood pressure medication to more than 25,000 bottles following multiple failed dissolution tests.
    • The affected products include Chlorthalidone Tablets, United States Pharmacopeia, 25 milligrams.
    • The Food and Drug Administration classified the September recall action as a Class II risk level.

    What to watch next

    • Further updates from the Food and Drug Administration regarding affected batch numbers.
    • Reports from Inventia Healthcare Limited on the root cause of the dissolution test failures.
    Sources used for this update (4)
    1. www.medicaldaily.com β€” RAPTURE Preworkout Recalled Nationwide Five Months After FDA ...
    2. www.nbcchicago.com β€” Thousands of bottles of Amazon-branded Acetaminophen recalled ...
    3. www.yahoo.com β€” Acetaminophen sold on Amazon recalled over complaints - Yahoo
    4. www.yahoo.com β€” This Amazon brand of medication is being recalled. See the ...
    confidence 100%
  7. Blood Pressure Medication Recall Expands Past 25,000 Bottles

    Inventia Healthcare Limited has expanded its voluntary nationwide recall of blood pressure medication to more than 25,000 bottles following multiple failed dissolution tests. The affected products include Chlorthalidone Tablets, United States Pharmacopeia, 25 milligrams. Patients using the medication are urged to contact their pharmacist to verify if their prescriptions are part of the recalled batches. The Food and Drug Administration classified the September recall action as a Class II risk level, which indicates that the chance of serious harm is remote and potential medical effects are temporary or reversible.

    Why it matters

    Drug quality failures involving blood pressure treatments present significant risks to patient management and blood pressure control. Dissolution defects prevent tablets from breaking down correctly in the body, which can reduce drug effectiveness. This safety action follows two separate manufacturer recalls initiated over a span of several months.

    What is confirmed

    • Inventia Healthcare Limited initiated two nationwide recalls of 25 milligram Chlorthalidone Tablets after the drugs failed dissolution specifications.
    • The first recall began on June 5 and covered 11,460 bottles.
    • The second recall began on September 3 and added 13,567 bottles, bringing the total to more than 25,000 bottles.
    • The Food and Drug Administration classified the September action as a Class II recall on September 17.

    What to watch next

    • Further updates from the Food and Drug Administration on the total return rate of affected Chlorthalidone bottles.
    • Additional regulatory actions or manufacturing plant inspections concerning Inventia Healthcare Limited.
    Sources used for this update (14)
    1. indiawest.com β€” FDA: Indian Pharma Giants Will Recall Medicines In US Over Quality ...
    2. medivascan.com β€” Drug recalls, by class and condition - MedivaScan
    3. drugrecallcheck.com β€” Check if your medication has been recalled | US Drug Recall ...
    4. medivascan.com β€” Blood pressure medication recalls | MedivaScan
    5. americanprosperity.com β€” ALERT: Blood Pressure Pills RECALLED | American Prosperity
    6. www.harmreport.com β€” Inventia Healthcare - Blood Pressure Pills Recalled Again
    7. www.yahoo.com β€” Blood pressure medication recall expands as more ... - Yahoo
    8. www.express.co.uk β€” Blood pressure drug urgently recalled after common tablet ...
    9. www.dailystar.co.uk β€” Blood pressure pills urgently recalled after failing safety ...
    10. blackamericaweb.com β€” 2026 Midterms, Voting Rights, and a Major Health Recall - Black America Web
    11. www.wral.com β€” AP Health News and Reporting Coverage, page 61 | WRAL
    12. www.goodhousekeeping.com β€” FDA Elevates New Eye Drop Recall to Class IIβ€”Here’s the Full List of Products
    confidence 100%
  8. FDA Recall for Chlorthalidone Blood Pressure Medication Expands to 25,000 Bottles

    The U.S. Food and Drug Administration has expanded a nationwide recall of blood pressure medication to more than 25,000 bottles. The affected diuretic tablets failed dissolution specifications, a defect that can reduce the effectiveness of the drug. Patients should check their prescriptions for batch number RISA24002 and an expiration date of March 2027. Inventia Healthcare Limited, based in India, initiated the voluntary recall after laboratory testing showed the tablets do not dissolve properly.

    Why it matters

    Chlorthalidone is a diuretic used to manage hypertension. Proper dissolution is required for the medication to function correctly inside the body. Failure to meet these specifications can leave patients with uncontrolled blood pressure.

    What is confirmed

    • The FDA issued a nationwide recall for blood pressure medication due to failed dissolution specifications.
    • More than 25,000 bottles of the medication are affected.
    • Inventia Healthcare Limited initiated the voluntary recall.
    • The affected medication is 25 mg chlorthalidone tablets.
    • Affected bottles carry batch number RISA24002 and an expiration date of March 2027.

    What to watch next

    • Further increases in the number of recalled bottles
    • FDA reports on patient adverse events linked to the dissolution failure
    Sources used for this update (3)
    1. www.oann.com β€” FDA: Over 25K bottles of blood pressure medication recalled nationwide – One America News Network
    2. www.sokolovelaw.com β€” Bard PowerPort Catheter Lawsuit Settlement Amounts (2026) - Sokolove Law
    3. latination.com β€” Blood pressure medication recalled nationwide: check your ...
    confidence 100%
  9. Nationwide Blood Pressure Medication Recall Affected Bottles Exceed 13,000

    The Food and Drug Administration issued a nationwide recall for 13,567 bottles of 25 mg chlorthalidone tablets after the diuretic failed laboratory dissolution testing. Inventia Healthcare Limited, an India-based pharmaceutical company, initiated the voluntary recall because the tablets do not dissolve properly, a defect that can alter how the drug functions inside the body. Patients taking the medication are advised to inspect their prescription bottles for batch number RISA24002 and an expiration date of March 2027 to determine if their medication is impacted by the quality issue.

    Why it matters

    Chlorthalidone is a widely used diuretic prescribed to treat high blood pressure. Quality test failures in dissolution can cause the medication to release incorrectly into the patient system, posing risks to cardiovascular management. Regulatory officials categorized the enforcement action under a Class II risk level.

    What is confirmed

    • The Food and Drug Administration issued a recall for 13,567 bottles of 25 mg chlorthalidone tablets.
    • Inventia Healthcare Limited is the manufacturer behind the voluntary recall.
    • The recalled tablets failed standard dissolution and quality testing.
    • The action is classified under the Food and Drug Administration's Class II risk level.
    • The affected batch number is RISA24002 with a March 2027 expiration date.
    • This represents the manufacturer's second recall of the tablets this year, affecting over 25,027 total bottles.

    What to watch next

    • Additional regulatory enforcement actions or manufacturer statements regarding the root cause of the dissolution failure
    • Reports of adverse health events linked to the affected batch number
    Sources used for this update (6)
    1. www.nbcdfw.com β€” FDA recalls 13,000+ bottles of chlorthalidone after quality test – NBC 5 Dallas-Fort Worth
    2. www.newsbreak.com β€” Trump Accounts will auto-enroll children, potentially adding 60 million accounts: Treasury - NewsBreak
    3. www.everydayhealth.com β€” Common Blood Pressure Pill Recalled Nationwide
    4. www.healthline.com β€” FDA Issues Class II Blood Pressure Medication Recall, Over 13,000 Bottles Affected
    5. www.news4jax.com β€” Thousands of bottles of blood pressure medication recalled nationwide - News4JAX ,WJXT Channel 4
    6. www.fox5atlanta.com β€” Recall of popular soft drink hits 77,000 cans after zero-sugar labels found on full-sugar soda | FOX 5 At....
    confidence 95%
  10. Nationwide Blood Pressure Medication Recall Issued by FDA

    Inventia Healthcare Limited is voluntarily recalling thousands of bottles of chlorthalidone blood pressure medication nationwide after the tablets failed standard FDA dissolution testing. The recall affects 25 mg tablets carrying batch number RISA24002 and an expiration date of March 2027. Officials classified the action under the Food and Drug Administration's Class II risk level. Patients taking the blood pressure medication are urged to inspect their prescription bottles to determine if their medication is impacted by the quality issue, which can alter how the drug functions inside the body.

    Why it matters

    Dissolution testing ensures that pharmaceutical tablets break down correctly in the body so the active ingredients can be properly absorbed. When medications fail these standards, patients risk receiving suboptimal doses of their treatment, which can lead to poorly managed health conditions. This event marks a regulatory intervention into the supply chain of widely prescribed cardiovascular medications.

    What is confirmed

    • Inventia Healthcare Limited is voluntarily recalling blood pressure medication nationwide.
    • The recalled medication is chlorthalidone.
    • The recall is classified under the FDA's Class II risk level.
    • The recall was triggered because the tablets failed FDA dissolution testing.
    • More than 25,000 bottles of the medication are involved in the recall.
    • The affected bottles contain 25 mg tablets with batch number RISA24002 and an expiration date of March 2027.

    Still unconfirmed

    • The current action represents a second recall of chlorthalidone from the same manufacturer.

    What to watch next

    • Further statements from Inventia Healthcare detailing the scope of the manufacturing defect
    • Additional updates from the FDA regarding affected distribution channels or injury reports
    Sources used for this update (19)
    1. The Hill β€” Blood pressure medication recalled nationwide under FDA’s Class II risk level
    2. WUSA9 β€” Blood pressure medication recalled nationwide after failing FDA dissolution testing
    3. Good Housekeeping β€” FDA Announces New Nationwide Blood Pressure Medication Recall
    4. newsnationnow.com β€” Blood pressure medication given Class II designation in recall update
    5. Newsday β€” Drug company recalls blood pressure medication chlorthalidone
    6. USA Today β€” Blood pressure medication recalled nationwide. See affected drug
    7. News4JAX β€” Thousands of bottles of blood pressure medication recalled nationwide
    8. Dallas News β€” FDA recalls blood pressure medication after quality issue
    9. Black Doctor β€” ALERT: Nationwide Recall of Blood Pressure Medication; 13,000+ Bottles
    10. qz.com β€” Inventia Healthcare recalls 25,000 bottles of chlorthalidone tablets
    11. Democrat and Chronicle β€” Blood pressure medication recalled over dissolution issue. What to know
    12. www.usatoday.com β€” Blood pressure medication recalled. See affected product
    confidence 100%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community